{"id":"pioglitazone-plus-dapaglifliozin","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Weight gain"},{"rate":"2-5%","effect":"Edema"},{"rate":"1-2%","effect":"Hypoglycemia"},{"rate":"1-2%","effect":"Nausea"},{"rate":"1-2%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL595","moleculeType":"Small molecule","molecularWeight":"356.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pioglitazone works by binding to PPAR-γ receptors in the nucleus, leading to increased expression of genes involved in glucose metabolism and insulin sensitivity. Dapagliflozin, on the other hand, inhibits the SGLT2 transporter in the kidneys, reducing glucose reabsorption and increasing glucose excretion in the urine.","oneSentence":"Pioglitazone is a thiazolidinedione that activates PPAR-γ, increasing insulin sensitivity, while dapagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:09.673Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT03794518","phase":"PHASE3","title":"Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2019-03","conditions":"Risk Reduction","enrollment":648}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pioglitazone Plus dapaglifliozin","genericName":"Pioglitazone Plus dapaglifliozin","companyName":"Hamad Medical Corporation","companyId":"hamad-medical-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pioglitazone is a thiazolidinedione that activates PPAR-γ, increasing insulin sensitivity, while dapagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys. Used for Type 2 diabetes, Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}